The Effect of Lanthanum Carbonate on Fibroblast Growth Factor 23 ( FGF23) in Chronic Kidney Disease
| Status: | Archived |
|---|---|
| Conditions: | Renal Impairment / Chronic Kidney Disease, Gastrointestinal |
| Therapuetic Areas: | Gastroenterology, Nephrology / Urology |
| Healthy: | No |
| Age Range: | Any |
| Updated: | 7/1/2011 |
| Start Date: | October 2009 |
| End Date: | October 2010 |
The Effect of Lanthanum Carbonate on Fibroblast Growth Factor 23 (FGF23 ) in Chronic Kidney Disease
The aim of the study is to assess the effects of the drug lanthanum carbonate (a phosphorus
binder drug) on c-terminal and on FGF23 levels in patients with Chronic Kidney Disease
(CKD).
Targeting FGF23 measurement in CKD patients may impact both the progression of kidney
disease and patient mortality.
This is a double blind randomized placebo controlled pilot study. Subjects with Chronic
Kidney Disease ( CKD) stages 3-5 who are not undergoing renal replacement therapy and have
not been started on phosphate binders will be randomized to either lanthanum carbonate 1500
mg daily or placebo for a 60 day treatment period. Patient doses will be increased up to a
maximum dose of 3000 mg if the serum phosphate is greater than 5.5 mg/dL.
We found this trial at
1
site
Click here to add this to my saved trials
